Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited (*) is a listed biopharmaceutical company that has been operating in the Chinese pharmaceutical industry for over 20 years. With an international perspective, the Group has established a solid business model in China covering drug development, clinical development, regulatory affairs, manufacturing, sales, and marketing. Currently, it markets a total of fourteen products in China. Lee's Pharmaceutical is dedicated to various fields, including cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology, and many other areas. In addition, there are over thirty products at various stages of development, including those from internal R&D and recently acquired licensing and distribution rights from various companies in the United States, Europe, and Japan. In 2010, Lee's Pharmaceutical was awarded second place in the "2010 Asia's Best Companies – (China Region) Best Small Company" by the Asian financial magazine "Finance Asia". In September 2011, Lee's Pharmaceutical was selected by Forbes as one of the Asia's Best 200 Companies (with revenue under US$1 billion). Lee's Pharmaceutical aims to become a successful biopharmaceutical group in Asia, providing treatments that cure diseases while improving physical and quality of life. A strategic shareholder of Lee's Pharmaceutical, Sigma Tau Group is a leading pharmaceutical research company in Rome, Italy. Sigma Tau's R&D activities and commercial technologies complement Lee's Pharmaceutical's current business, bringing important business synergies. Zhaoke Pharmaceutical (Hefei) Co., Ltd. (*) is a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited (a Hong Kong listed company, stock code: 00950), located in the High-tech Industrial Development Zone of Hefei. Established in 1994, the company has developed into a modern pharmaceutical enterprise integrating scientific research, production, and trade, leveraging technical advantages in biochemistry and biology. Zhaoke Pharmaceutical adheres to a scientific development outlook, possesses rigorous basic drug R&D and clinical research teams, and requires independent intellectual property rights for each new product developed. All drugs are completed from R&D to market launch by itself, with a comprehensive quality assurance system. Zhaoke Pharmaceutical (Guangzhou) Co., Ltd. is a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited (a Hong Kong listed company, stock code: 00950), located in the Pearl River Industrial Park, Nansha New District, Guangzhou City, Guangdong Province, covering an area of 30 mu. As the headquarters of Lee's Pharmaceutical Holdings Limited in mainland China, Zhaoke Pharmaceutical (Guangzhou) Co., Ltd. has a total investment of US$32 million. Construction commenced in March 2012, took 2 years and 9 months, and officially became operational on December 1, 2014. Zhaoke Pharmaceutical (Guangzhou) Co., Ltd. primarily operates the production of new compound drugs or active ingredient drugs (including APIs and preparations), new anti-cancer drugs, new cardiovascular drugs, and new nervous system drugs, new drugs and preparations using biotechnology, new dosage forms and products using new technologies such as sustained-release, controlled-release, targeted, and transdermal absorption, and biomedical materials and products (excluding processing of human corpses and specimens, human organs and tissues and their specimens). In addition to selling its own products, the company also provides related technical consulting and technical services.